☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
CFTR gene
Vertex's Symdeko (tezacaftor/ivacaftor and ivacaftor) Receives TGA's Approval for Cystic Fibrosis with CFTR Gene Mutation in Austr...
March 13, 2019
Vertex's Kalydeco (ivacaftor) Receives Health Canada's Approval for Cystic Fibrosis (CF) with CFTR Gene Mutation in Children Aged...
January 29, 2019
Vertex Pharmaceuticals' Orkambi (lumacaftor+ivacaftor) Receives EU Approval for Cystic Fibrosis (CF) with Mutation in CFTR gene in...
January 21, 2019
Vertex's Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic Fibrosis (CF) Aged 2 to 5 yrs.
December 14, 2018
Vertex Receives EU's MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged ≥12yrs. with Mut...
November 2, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.